Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00126997 |
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
Condition | Intervention | Phase |
---|---|---|
Measles Mumps Rubella Chickenpox |
Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety Study |
Official Title: | Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals’ Live Attenuated Measles-Mumps-Rubella-Varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life |
Ages Eligible for Study: | 11 Months to 21 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 104020 |
Study First Received: | August 4, 2005 |
Last Updated: | August 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00126997 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Prophylaxis measles, mumps, rubella and chickenpox |
Herpes Zoster Mouth Diseases Paramyxoviridae Infections Measles Chickenpox Healthy Rubella Togaviridae Infections |
Herpesviridae Infections Virus Diseases DNA Virus Infections Chicken pox Stomatognathic Diseases Salivary Gland Diseases Mumps |
Rubivirus Infections Parotid Diseases RNA Virus Infections Morbillivirus Infections |
Rubulavirus Infections Parotitis Mononegavirales Infections |